Cargando…

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer

Human epidermal growth factor receptor 2 (HER2) gene amplification in circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) might be useful for modifying Herceptin therapy in breast cancer. In the process of investigating the utility of a microfluidic platform for detecting HER2 gene am...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnamurthy, Savitri, Bischoff, Farideh, Ann Mayer, Julie, Wong, Karina, Pham, Tam, Kuerer, Henry, Lodhi, Ashutosh, Bhattacharyya, Anirban, Hall, Carolyn, Lucci, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639661/ https://www.ncbi.nlm.nih.gov/pubmed/23634290 http://dx.doi.org/10.1002/cam4.70

Ejemplares similares

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells
por: Woodward, Wendy A., et al.
Publicado: (2014)

Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Cancer in twin pairs discordant for smoking: The Nordic Twin Study of Cancer
por: Korhonen, Tellervo, et al.
Publicado: (2022)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

A small molecule inhibitor of HER3: a proof-of-concept study
por: Colomba, Audrey, et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Dissecting transcriptional amplification by MYC
por: Nie, Zuqin, et al.
Publicado: (2020)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Heterotaxy Syndrome: Discordant Growth
por: Yadav, Pratiksha, et al.
Publicado: (2021)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein
por: Pawlik, Timothy M, et al.
Publicado: (2006)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Dissemination of validated health literacy videos: A tailored approach
por: Blee, Shannon M., et al.
Publicado: (2022)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer
por: Elsayegh, Nisreen, et al.
Publicado: (2018)

Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues
por: Dobbs, Jessica L., et al.
Publicado: (2015)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
por: Sun, Qi, et al.
Publicado: (2022)

Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc
por: Lewis, L Michelle, et al.
Publicado: (2018)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Non-disseminated breast cancer : controversial issues in management /
Publicado: (1993)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate‐resistant colon cancer cells
por: Cai, Mengdi, et al.
Publicado: (2018)

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
por: Chen, Shukun, et al.
Publicado: (2018)

Detection of HER2(+) Breast Cancer Cells using Bioinspired DNA‐Based Signal Amplification
por: Rafiee, Sarah D., et al.
Publicado: (2020)

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
por: Shi, Ji‐Hua, et al.
Publicado: (2019)

SPHK1‐induced autophagy in peritoneal mesothelial cell enhances gastric cancer peritoneal dissemination
por: Yin, Songcheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_po9m2vpq3379nhbiu9tthu7jim